Blood test could spare stomach cancer patients from unnecessary chemo

NCT ID NCT07508956

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a simple blood test that detects tiny bits of tumor DNA (ctDNA) can help doctors decide which stomach cancer patients need extra chemotherapy after surgery. About 304 people with locally advanced stomach cancer will be randomly assigned to either standard care or treatment guided by the blood test. The goal is to see if this approach can reduce unnecessary treatments and side effects while keeping survival rates just as good.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••